Literature DB >> 19388165

Contribution of interactions between complement inhibitor C4b-binding protein and pathogens to their ability to establish infection with particular emphasis on Neisseria gonorrhoeae.

Anna M Blom1, Sanjay Ram.   

Abstract

Complement activation and resulting opsonisation with C3b form key arms of the innate immune defense against infections. However, a wide variety of pathogens subvert complement attack by binding host complement inhibitors, which results in diminished opsonophagocytosis and killing of bacteria by lysis. Human C4b-binding protein (C4BP) binds Neisseria gonorrhoeae and Streptococcus pyogenes, both uniquely human pathogens. This binding specificity is circumvented by other bacterial species, which bind C4BP from numerous mammalian hosts that they infect. Binding of C4BP to Neisseria is mediated by outer membrane porin proteins and appears to be one of the main factors mediating serum resistance. Targeting C4BP binding sites on bacterial surfaces with vaccine-induced antibodies may block binding of C4BP and enhance a common vaccine design strategy that depends on the generation of complement-dependent bactericidal and opsonophagocytic antibody activities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19388165     DOI: 10.1016/j.vaccine.2008.11.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Neisseria gonorrhoeae host adaptation and pathogenesis.

Authors:  Sarah Jane Quillin; H Steven Seifert
Journal:  Nat Rev Microbiol       Date:  2018-02-12       Impact factor: 60.633

2.  Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation.

Authors:  Panisadee Avirutnan; Richard E Hauhart; Pawit Somnuke; Anna M Blom; Michael S Diamond; John P Atkinson
Journal:  J Immunol       Date:  2011-06-03       Impact factor: 5.422

3.  Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7.

Authors:  Srinjoy Chakraborti; Sunita Gulati; Bo Zheng; Frank J Beurskens; Janine Schuurman; Peter A Rice; Sanjay Ram
Journal:  Infect Immun       Date:  2020-01-22       Impact factor: 3.441

4.  Epididymal C4b-binding protein is processed and degraded during transit through the duct and is not essential for fertility.

Authors:  Mayumi I Nonaka; Eva Zsigmond; Akihiko Kudo; Hayato Kawakami; Kaoru Yoshida; Manabu Yoshida; Natsuko Kawano; Kenji Miyado; Masaru Nonaka; Rick A Wetsel
Journal:  Immunobiology       Date:  2014-11-11       Impact factor: 3.144

5.  Mutual exclusivity of hyaluronan and hyaluronidase in invasive group A Streptococcus.

Authors:  Anna Henningham; Masaya Yamaguchi; Ramy K Aziz; Kirsten Kuipers; Cosmo Z Buffalo; Samira Dahesh; Biswa Choudhury; Jeremy Van Vleet; Yuka Yamaguchi; Lisa M Seymour; Nouri L Ben Zakour; Lingjun He; Helen V Smith; Keith Grimwood; Scott A Beatson; Partho Ghosh; Mark J Walker; Victor Nizet; Jason N Cole
Journal:  J Biol Chem       Date:  2014-09-29       Impact factor: 5.157

Review 6.  Evasion Mechanisms Used by Pathogens to Escape the Lectin Complement Pathway.

Authors:  Anne Rosbjerg; Ninette Genster; Katrine Pilely; Peter Garred
Journal:  Front Microbiol       Date:  2017-05-12       Impact factor: 5.640

Review 7.  Gonorrhea - an evolving disease of the new millennium.

Authors:  Stuart A Hill; Thao L Masters; Jenny Wachter
Journal:  Microb Cell       Date:  2016-09-05

8.  Pilus phase variation switches gonococcal adherence to invasion by caveolin-1-dependent host cell signaling.

Authors:  Michaela Faulstich; Jan-Peter Böttcher; Thomas F Meyer; Martin Fraunholz; Thomas Rudel
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823

9.  Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm.

Authors:  Yasser Ali Aldhamen; Sergey S Seregin; Andrea Amalfitano
Journal:  Front Immunol       Date:  2011-09-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.